Clinical trials: Lung
Pneumonia
Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia
This research study is being done to determine the appropriate dose of steroids and the appropriate duration for steroid use to reduce inflammation in severe pneumonia needing a form of breathing support.
- Trial name
- NCT03852537
- Testing
- Methylprednisolone, Usual Care
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Chronic Obstructive Pulmonary Disease (COPD)
Stepping up to Health - for Veterans With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the efficacy of an internet-mediated pedometer based intervention that is designed to increase walking and improve function among veterans with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01102777
- Testing
- automated internet-mediated walking program, Usual Care
- Where
- United States
- Volunteers
- 307 people
- Sponsor
- VA Office of Research and Development
Flu, Human, Influenza, Human
Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects
The aim of the study is to identify what sender/signal combinations are most persuasive in encouraging low socioeconomic males living in the U.S. to take-up seasonal flu vaccination.
- Conditions
- Flu, Human, Influenza, Human, Covid19
- Trial name
- NCT04160975
- Testing
- Video about safety and effectiveness of adult seasonal flu vaccination
- Where
- United States
- Volunteers
- 3,245 people, healthy volunteers welcome
- Sponsor
- Harvard University
Pulmonary Arterial Hypertension
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
IMPAHCT-FUL: Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (LTE) Trial was a follow up study to establish the long-term safety of AV-101.
- Trial name
- IMPAHCT-FUL (NCT05557942)
- Testing
- AV-101
- Where
- 72 sites in United States, Argentina and 18 more
- Volunteers
- 186 people
- Sponsor
- Aerovate Therapeutics
Pulmonary Disease, Chronic Obstructive
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
The primary objective is to compare the efficacy of UMEC/VI Inhalation Powder (62.5/25 mcg) once-daily with tiotropium (18 mcg) once-daily over 12 weeks for the treatment of subjects with COPD who have received tiotropium and…
- Trial name
- NCT01899742
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
- Where
- 64 sites in United States, Argentina and 8 more
- Volunteers
- 497 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy
The decrease in physical activity due to increasing dyspnoea that over time leads to a steadily worsening condition and increasing restriction of physical functioning is a key problem for COPD patients and affects even the early…
- Trial name
- NCT02173769
- Testing
- Spiriva® Respimat®, Striverdi® Respimat®
- Where
- 701 sites in Germany
- Volunteers
- 1,845 people
- Sponsor
- Boehringer Ingelheim
Covid-19
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.
- Trial name
- NCT06016556
- Testing
- nirmatrelvir, ritonavir
- Where
- 3 sites in Saudi Arabia
- Volunteers
- 250 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy
The purpose of this study is to determine if Pemetrexed plus Carboplatin plus Bevacizumab plus Enzastaurin, followed by maintenance Bevacizumab plus Enzastaurin can extend survival time without disease progression in the…
- Trial name
- NCT00533429
- Testing
- enzastaurin, pemetrexed, carboplatin
- Where
- 12 sites in United States
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
The primary objective of this study is to determine the major objective response rate of OSI-774 in participants with unresectable or metastatic bronchioloalveolar cell variant of non-small cell lung cancer.
- Trial name
- NCT00590902
- Testing
- OSI-774: erlotinib, TarcevaTM
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Asthma
The Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial
This research study will compare the treatment effects of three different asthma medications in asthma subjects whose asthma is well controlled when they take fluticasone, an inhaled corticosteroid.
- Trial name
- NCT00156819
- Testing
- fluticasone, montelukast, Fluticasone plus salmeterol
- Where
- 19 sites in United States
- Volunteers
- 500 people
- Sponsor
- JHSPH Center for Clinical Trials
Asthma
Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
The purpose of this Phase II study is to evaluate efficacy and safety of inhaled formoterol fumarate in the Pressair DPI compared to the Foradil Aerolizer in patients with mild to moderate asthma.
- Trial name
- NCT01641081
- Testing
- Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose
- Where
- 29 sites in United States
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Lung Cancer
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed.
- Trial name
- NCT00104728
- Testing
- ZD1839
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer
This randomized phase II trial studies how well pemetrexed disodium with or without erlotinib hydrochloride works in treating patients with stage IIIB-IV or recurrent non-small cell lung cancer.
- Conditions
- Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma
- Trial name
- NCT00950365
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
- Where
- 5 sites in United States
- Volunteers
- 79 people
- Sponsor
- Albert Einstein College of Medicine
Non-Small Cell Lung Cancer
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
The main objective of this study was to evaluate the anti-tumor activity of gimistotug (BGB-A445) plus investigational agents in participants with non-small cell lung cancer (NSCLC).
- Trial name
- NCT06029127
- Testing
- Gimistotug, Docetaxel, BGB-15025
- Where
- 18 sites in China, South Korea
- Volunteers
- 35 people
- Sponsor
- BeiGene
SARS-CoV-2 Infection, COVID-19
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
This study will compare the safety and tolerability of lyophilized BNT162b2 presented in single dose vials to those of frozen-liquid BNT162b2 in multidose vials and determine whether the immune response is noninferior.
- Trial name
- NCT04816669
- Testing
- BNT162b2
- Where
- 21 sites in United States
- Volunteers
- 629 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Asthma
Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma
This is a multicentre, randomized, single-blind, active-controlled, parallel-group phase III local registration study for a treatment period of 12 weeks.
- Trial name
- NCT01687283
- Testing
- fluticasone propionate inhalation solution, budesonide suspension
- Where
- 25 sites in China
- Volunteers
- 316 people
- Sponsor
- GlaxoSmithKline
Chronic Lymphocytic Leukemia
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
This research study will look at the effects (good or bad) of administering cyclophosphamide, fludarabine, and rituximab. Clinical studies with combination therapy have shown higher response rates than using single drugs, and…
- Trial name
- NCT00280241
- Testing
- Fludarabine, Cyclophosphamide, Rituximab
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Pittsburgh
Interstitial Lung Diseases
Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease
The purpose of this multi-centered, NIH-sponsored study is to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).
- Trial name
- NCT04855305
- Testing
- Hyperpolarized 129Xe
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Atrial Fibrillation
nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation
To demonstrate safety and effectiveness of nMARQ Catheter System [nMARQ] compared with THERMOCOOL® Navigational Family of catheters in treating subjects with drug-refractory symptomatic paroxysmal atrial fibrillation (PAF).
- Trial name
- NCT01824394
- Testing
- nMARQ Navigation Catheters, NaviStar ThermoCool Catheters
- Volunteers
- 481 people
- Sponsor
- Biosense Webster, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.